Comparative Pharmacology
Head-to-head clinical analysis: MINZOYA versus TRI LEGEST 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINZOYA versus TRI LEGEST 21.
MINZOYA vs TRI-LEGEST 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH), inhibits ovulation, alters cervical mucus and endometrium.
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
One tablet orally once daily for 21 days, followed by 7 tablet-free days. Each tablet contains norgestimate 0.18 mg/ethinyl estradiol 0.025 mg (days 1-7), norgestimate 0.215 mg/ethinyl estradiol 0.025 mg (days 8-14), norgestimate 0.25 mg/ethinyl estradiol 0.025 mg (days 15-21).
None Documented
None Documented
Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norgestimate active metabolite (norelgestromin): 22-36 hours (mean ~28 hours). Steady-state achieved within 5-10 days.
Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination.
Renal: approximately 50-60% as metabolites; fecal: approximately 40-50% (ethinyl estradiol and norgestimate metabolites excreted in bile and feces); less than 1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive